IRWD Ironwood Pharmaceuticals Inc.

12.42
-0.3  -2%
Previous Close 12.72
Open 12.82
Price To Book -9.7
Market Cap 1917830462
Shares 154,414,691
Volume 1,361,700
Short Ratio
Av. Daily Volume 1,515,374

SEC filingsSee all SEC filings

  1. 8-K - Current report 19512274
  2. 8-K - Current report 19510739
  3. 8-K - Current report 19506580
  4. 8-A12B/A [Amend] - Registration of securities [Section 12(b)] 19506288
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals 181225167

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2H 2019.
Olinciguat (IW-1701) - STRONG-SCD
Sickle Cell disease
Approval announced August 21, 2017.
DUZALLO (LESINURAD AND ALLOPURINOL)
Hyperuricemia associated with gout
Phase 2 data due 2H 2019.
IW-1973
Diabetic nephropathy
sNDA approval announced January 26, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults
Chronic idiopathic constipation (CIC)
Phase 3b data due mid-2019.
Linaclotide
Irritable Bowel Syndrome with Constipation (IBS-C)
Phase 2a data released April 2016. Development to be discontinued due to disappointing data
IW-9179
Gastroparesis
Phase 3 trial initiation announced June 21, 2018.
IW-3718
Gastroesophageal reflux disease (GERD)
No additional trials planned.
IW-1701
Achalasia
Phase 2 data due 2H 2019.
IW-1973
Heart failure HFpEF
Phase 2 trial to be initiated 1Q 2018.
MD-7246
Irritable Bowel Syndrome
Phase 2 trial to be initiated 1Q 2019.
MD-7246
Irritable Bowel Syndrome
Phase 1 trial initiation announced January 23, 2019 with data due 2H 2019.
IW-6463
Healthy volunteers

Latest News

  1. Ironwood Pharmaceuticals Initiates Phase 1 Trial of IW-6463, the First CNS-penetrant sGC Stimulator to Enter Clinical Trials
  2. See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.
  3. How to spot risky biotech companies and six to avoid now
  4. Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C
  5. Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in China for the Treatment of Adults with IBS-C
  6. Ironwood to Get New CEO, Current CEO to Head Latest Spinoff
  7. Ironwood Pharmaceuticals Appoints Michael Shetzline, M.D., Ph.D. as Chief Medical Officer
  8. Ironwood Pharmaceuticals Picks AstraZeneca Executive to Be Next CEO
  9. Ironwood co-founder, CEO will step down to head new spinout
  10. Ironwood Pharmaceuticals Announces Chief Executive Officers to Lead Ironwood and Cyclerion, Effective Upon Upcoming Separation
  11. Ironwood/Allergan Settle Linzess Patent Litigation With Mylan
  12. Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
  13. Ironwood and Allergan Announce Settlement with Mylan Resolving LINZESS® (linaclotide) Patent Litigation
  14. Hedge Funds Are Betting On Ironwood Pharmaceuticals, Inc. (IRWD)
  15. Edited Transcript of IRWD earnings conference call or presentation 6-Nov-18 1:30pm GMT
  16. Is Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Overpaying Its CEO?
  17. Why Is Ironwood (IRWD) Up 6.7% Since Last Earnings Report?